# Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

> **NCT07708714** · PHASE1,PHASE2 · RECRUITING · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 250 (estimated)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Anemia in Children

## Interventions

- **DRUG:** hydroxycarbamide

## Key facts

- **NCT ID:** NCT07708714
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-13
- **Primary completion:** 2030-11-30
- **Final completion:** 2032-11-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-07-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708714, "Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07708714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*